Evidence map›Paper›PMID 25615608›Full record

ArticleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2015

Allogeneic Hematopoietic Cell Transplantation for Children with Sickle Cell Disease Is Beneficial and Cost-Effective: A Single-Center Analysis.

Staci D Arnold, Zhezhen Jin, Stephen Sands, Monica Bhatia, Andrew L Kung, Prakash Satwani

Registry-linked trialOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04523376 (Closely Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation With TCRαβ+ T Cell and B Cell Depletion For Patients With Sickle Cell Disease and Thalassemia Major), which is not on this map. Cited by 16 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 3 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04523376 nacompletednot on this mapstarted 2020, after this paper: background citation

Closely Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation With TCRαβ+ T Cell and B Cell Depletion For Patients With Sickle Cell Disease and Thalassemia Major

TypeinterventionalSponsorTimothy OlsonRan2020 to 2025Enrolled8ConditionsSickle Cell Disease, Thalassemia MajorArmsCliniMACS
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 3 syntheses or guidelines pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Health State Utilities for Sickle Cell Disease: A Catalog Prepared From a Systematic Review.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2022
    Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Review
  7. Application of validated mapping algorithms between generic PedsQL scores and utility values to individuals with sickle cell disease.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2022
    Article
  8. Increasing access to allogeneic hematopoietic cell transplant: an international perspective.Hematology. American Society of Hematology. Education Program · 2021
    Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. National Institutes of Health Blood and Marrow Transplant Late Effects Initiative: The Healthcare Delivery Working Group Report.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2017
    Review
  16. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Staci D ArnoldDepartment of Pediatrics, Columbia University Medical Center, New York, New York. Electronic address: sa2812@columbia.edu.
Zhezhen JinMailman School of Public Health, Columbia University Medical Center, New York, New York.
Stephen SandsDepartment of Pediatrics, Columbia University Medical Center, New York, New York.
Monica BhatiaDepartment of Pediatrics, Columbia University Medical Center, New York, New York.
Andrew L KungDepartment of Pediatrics, Columbia University Medical Center, New York, New York.
Prakash SatwaniDepartment of Pediatrics, Columbia University Medical Center, New York, New York.
Columbia University Irving Medical Center · USColumbia University · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Limited data exist regarding health care utilization (HCU) in patients receiving allogeneic hematopoietic cell transplantation (alloHCT) for sickle cell disease. Financial data from 2002 to 2011 were analyzed for 26 alloHCT patients and 48 control subjects (referred but without alloHCT). HCU of alloHCT was determined over 3 time periods: pre-alloHCT, during alloHCT (day 0 to day +365), and post-alloHCT. The median total cost per patient during the alloHCT year was $413,000 inpatient and $18,000 outpatient. Post-alloHCT HCU decreased when compared with pre-alloHCT and control subjects. The median cost of post-alloHCT outpatient visits per patient was significantly less when compared with pre-alloHCT (P = .044). The median cost of post-alloHCT inpatient visits per patient approached significance when compared with those pre-alloHCT (P = .079). Sixteen post-alloHCT patients, 19 control subjects, and 14 unaffected siblings were surveyed using Pediatric Quality of Life Inventory and EuroQOL questionnaires; however, the questionnaire scores across all 3 patient groups were not statistically significant (P = .2638). When adjusted for health-related quality of life, the analysis suggested alloHCT has a positive impact on health-related quality of life over control subjects. These pilot data support our hypothesis that alloHCT in children with sickle cell disease reduces HCU compared with control subjects without alloHCT.

Indexed as

Cost-Benefit AnalysisAdolescentAnemia, Sickle CellCase-Control StudiesChildChild, PreschoolChronic DiseaseHematopoietic Stem Cell TransplantationHumansInfantPilot ProjectsQuality of LifeSurveys and QuestionnairesTransplantation, HomologousCostOutcomesPediatricQuality of lifeSickle cell diseaseTransplant

Identifiers

PMID25615608
PMCPMC5605133
OpenAlexW1988043463

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.